the authors' discretion. It might be better to simply create a table of the nutraceuticals you will accept and any you will not accept and provide your justifications. Additionally, give many and provide the criteria for adding others not listed.
• On page 8, line 40, under "Outcome measures," it states: "Primary outcome measure will be an assessment of depression symptomology (e.g., mean differences in scores on MADRS, BDRS, etc.)." It doesn't state what will happen if the results present multiple outcomes, i.e., MADRS and BDRS. Will both outcome measures be included in the meta-analysis? Will only one, and if so, which one will you choose and how will that decision be made? How will you cope with these issues? • On page 10, line 19, it states that "there will be an assessment for publication bias." However, but it does not say what that assessment will be. Will the authors make funnel plots? Moreover, will these assessments be only for the main analysis or for the subgroup analyses as well? Publication bias is an especially relevant concern in a field where there are a lot of activist researchers.
• On page 10, line 26, it states: "If I2 is >50% then the study will be considered to have a substantial heterogeneity and will be included in the systematic review, but it will not be included in the proposed meta-analysis." This is a bit unusual: I2 is a summary statistic calculated for the meta-analysis as a whole, not for individual studies in a meta-analysis Please clarify more precisely what you mean here.
• On page 10, line 37, it states: "Results will be reported as mean differences (MD) with 95% confidence intervals (CI)." It is only possible to report mean differences if all of the results are reported on a single scale, such as BDRS, MADRS etc. Since you are accepting multiple scales, it is impossible to have a single mean difference, you would have to use another outcome measure, like standardized mean difference (SMD).
• On page 10, line 40, under "Subgroup analysis," it becomes abundantly clear that the authors' first meta-analysis is one of all nutraceuticals vs placebo for the treatment of the depressive symptoms of bipolar disorder. "The following subgroup analyses will be performed if there is significant heterogeneity across the studies (if I2>50%). Subgroup analyses will include different phases of BD and different groups of nutraceuticals," and then you proceed to list vitamins, minerals, fatty acids and amino acids as subgroups. It is only clear at this point that the subgroup analysis will be the meat of the paper. This is a page and a half before the end of a 12-page protocol. One of the things that strikes me most explicitly at this point is how bizarre it is to have some of these categories: vitamins have very little in common with one another vis-à-vis their mechanisms of action or effects. If minerals are defined as supplementation with particular elements necessary for health, couldn't lithium fall under mineral supplementation? It iss fair to assume that Potassium's action, in the same period as Lithium's action, will be as different in action from Iron as it is from Lithium. Why lump them together?
• On page 11, line 17, under "Sensitivity analysis," the phrasing of how the sensitivity analyses will be completed is just too vague. Please state all the comparisons you will make and the statistics you will use to compare studies. Also, state how you will handle studies that do not present separate data for gender, age, etc. This is far from a protocol for which I would recommend publication and I have many reservations about it. It would require a major revision. It seems that the subgroup meta-analyses of "individual agents," (page 11, line 10) will be interesting, but the main analysis and other lumped analyses don't seem like they make much sense, given the widely varying mechanisms of action being lumped together. I would propose a rewrite of the protocol where it is simply a meta-analysis of individual agents or agents sharing a common mechanism. The molecular geneticists talk about hypothesis-free investigations, which is very different meta-analysis often emphasizes avoidance of bias and sensitivity to possible biases. However, even the molecular geneticists when they analyze a gene set of 900,000 genes in a hypothesis free manner, do not test first when the gene set predicts a given disease versus controls. The focus on the most heterogeneous results. The logic of doing this I would guess is that if a grouping of many agents and the results have significant heterogeneity, you can discard the grouping. But, what if two agents sharing a common mechanism albeit a mechanism operating in a different direction, and one of them has a beneficial effect and another one has a detrimental effect. The results are not heterogeneous but are meaningful. The most common likely shared mechanism would be an enthusiastic investigator's for their particular agent and publication bias leading to the selection for bias. The strategy does seem like a hypothesisfree strategy, with many sensitivity analysis around variable which probable do not make any difference. An alternative strategy would be a hypothesis-driven strategy. For some nutraceuticals there are hypotheses which you can state and test for evidence that it just confirms these hypotheses. If the hypotheses are stated up-front in the protocol, and you confirm them, it will make any finding much more plausible and less subject to criticism of data dredging.
VERSION 1 -AUTHOR RESPONSE
Reviewer ( Add Bipolar depression as it is misleading to say bipolar disorder if you are restricting the review to bipolar depression.
Response:
We thank you for your suggestion and have amended the systematic review so it is not restricted to bipolar depression.
Strengths and limitations
Why restrict the review to bipolar depression and not have this as a limitation? It would be a stronger review if bipolar disorder was reviewed as nutraceuticals may be taken continuously and may affect the degree of mood instability, depression and hypo/mania experienced. Papers may need to be excluded because they do not specify bipolar depression.
Response:
We thank you for your suggestion and have broadened the review to include both mania and depression. This has been reflected throughout the protocol by several changes.
Intro:
Typo: serotonin serotonin= selective serotonin
Response:
This has been amended.
The two previous systematic reviews ( Sarris et al., 201115 and Sylvia et al., 201216) were not restricted to bipolar depression.
Response:
As suggested, we will also no longer restrict to bipolar depression only.
Search Strategy:
Typo: Search Stategy= Search Strategy Response:
We apologise but we are unable to locate this error in the manuscript. We agree that it should be corrected.
Consider adding: anti-inflammatory, homeopathic Response:
We thank you for your suggestion however we have chosen not to include these key words. Antiinflammatory is likely to return additional agents which will not be within the scope of the review (e.g. Non-steroidal anti-inflammatory medications).
Identification of eligible studies:
It is stated that: The initial search will be conducted by one lead reviewing author to identify relevant articles. A second independent reviewing author will confirm 10% of each exclusion category prior to the lead reviewing author moving onto the next stage of screening. It would be better practice if 2 authors independently reviewed all titles/abstracts and any disagreements discussed and if agreement cannot be reached then the full article is included in the next stage.
Response:
We thank you for your suggestion, we have now amended the protocol. Two independent authors will review all titles/abstract screens and any discrepancies will be reviewed by a third author who will act as an adjudicator. The following text has been amended to reflect this: "A second independent reviewing author will independently screen the titles and abstracts. If there is any discrepancies, an experienced third author will act as adjudicator to decide on inclusion into full-text review." [Section: Identification of eligible studies, page 10, line 8] Subgroup analysis:
Typo: thestudies= the studies Response:
ABBREVIATIONS:
Formatting error: HAM-D Hamilton Depression Rating Scale
We apologise but we are unable to locate this error in the manuscript.
Reviewer: 2 The protocol appears to suggest the authors intend to conduct a systematic review and meta-analysis which combines all nutraceuticals for the treatment of bipolar disorder together in a single summary statistic. This would be akin to planning a meta-analysis of "chemical for cancer" and lumping together both carcinogens and therapeutic agents.
This seemed a bizarre premise, and it was only upon reaching the section on page 10 titled "Subgroup analysis" that it became clear the authors expected to reject the main meta-analysis because the heterogeneity of the main meta-analysis would be too large and they would therefore be able to do more reasonable groupings of studies, including according to individual treatment agents, classes of treatment agents, phase of bipolar disorder and combined vs monotherapy.
While this is an acceptable way to propose a protocol, it does seem like burying unnecessarily the majority of what the study intends to accomplish. Therefore, it might make sense to state the author's intent more explicitly in the earlier portions of the protocol. For example:
• On page 5, line 44, the authors state that "If sufficient data and homogeneity are established, a meta-analysis will be conducted." To my reading, the authors never explicitly define what sufficient data would mean. Sufficient homogeneity is only defined 5 pages later, near the end of the protocol.
Response:
o This section has been clarified by including the following: "If there is sufficient data within two studies or more and homogeneity established, a meta-analysis will be conducted to assess the effect of nutraceuticals compared to placebo. If the studies demonstrate considerable heterogeneity then sub-analyses will be performed. • On pages 6 and 7, under the heading "Search Strategy," the phrasing is a bit odd. A Boolean search strategy is proposed starting on page 6, line 40 and going to page 7, line 10. Then the paper states: "In addition, other common key terms will be used…" Is this a separate search that will be conducted? Will these terms be interspersed in the first search? It's not clear from the phrasing. If this is just another search that will be conducted, and the additional articles identified in this search will be added to articles in the first search, it should be stated as such. Or, you can simply have one giant Boolean statement wherein it's stated: (Search Strategy 1) OR (Search Strategy 2).
This sentence has been rephrased to: "In addition, other common, non-MESH key terms will be included in the coinciding sections of the search". We have also included an Appendix which outlines the full search strategy for each database. The following sentence is included: "The full search strategy for each database can be found in Supplementary File 1." [Section: Search strategy, page 7 lines 14 and 21, respectively]
• On page 8, line 10, it's stated that "Subgroup analyses will be performed to determine the effects of the study medication specifically on the active depressive phase of BD." This phrasing is vague, how will this data be extracted? Will you only accept the data if it's separated out by the authors of the study?
We will explore data that has depression outcomes on validated depression scales in the subgroup analyses. The same approach will be employed for mania symptoms.
• On page 8, line 14, it's stated: "depression must be assessed using standardized scales such as…" and then the scales are listed. In American English, the phrase "such as" is very vague. Are the scales you have listed the only ones you will accept, or are there others? Please just list all the scales you will accept or the criteria for including or excluding those not listed.
This has been rephrased to "must be assessed using the following standardised scales:" [Section: Types of studies, page 8, line 15]
• On page 8, line 24, it says, "Appropriate cut-off scores will be used for relevant severity of disorder in each study." This phrasing is very vague. What are the cut-off scores? Where will you be getting the cut-offs, how can you show that a cut-off score on one scale is equivalent to the cut-off score on another scale?
The following has been included for clarification: "Appropriate cut off scores will be used for relevant severity of disorder in each study, as determined by or established for each scale. For example, if a study was interested in at least moderate level of depression and utilising the MADRS, a cut off score of 20 or above would be appropriate given 0-6 is considered recovered, o In the interest of being transparent about what will be accepted under these definitions, we will list all agents that are returned from the search. The following sentence has been included: "Following the initial search, a table of agents which are included and excluded through the systematic review process will be provided." [Section: Types of interventions, page 9, line 6]
• On page 8, line 40, under "Outcome measures," it states: "Primary outcome measure will be an assessment of depression symptomology (e.g., mean differences in scores on MADRS, BDRS, etc.)." It doesn't state what will happen if the results present multiple outcomes, i.e., MADRS and BDRS. Will both outcome measures be included in the meta-analysis? Will only one, and if so, which one will you choose and how will that decision be made? How will you cope with these issues?
The following has been included for clarity: "In the case of multiple outcome measures in the study, only the primary outcome will be included in the systematic review and potential meta-analysis. Any secondary outcomes will not be included as they are likely to be underpowered." [Section: Outcome measures, page 9, line 12]
• On page 10, line 19, it states that "there will be an assessment for publication bias." However, but it does not say what that assessment will be. Will the authors make funnel plots? Moreover, will these assessments be only for the main analysis or for the subgroup analyses as well? Publication bias is an especially relevant concern in a field where there are a lot of activist researchers.
Funnel plots will be used to assess publication bias, as suggested. Publication bias will be explored based on the primary outcome. It would be expected that the bias would be similar in secondary outcomes. The following has been added: "Publication bias will be assessed via funnel plots." [Section: Identification of eligible studies, page 11 line 8]
This has been edited for clarification: "If I2 is >50% then the studies will be considered to have a substantial heterogeneity and will be included in the summarising sections of the systematic review, but the proposed meta-analysis will not be conducted." [Section: Identification of eligible studies, page 11 line 11]
We have changed the statistic to standardised mean differences, accordingly. In addition, the following sentence has been included: "Treatment effects will be measured by standardised mean differences with 95% confidence intervals to allow for differences in interpretation of scores across the scales." [Section: Assessment of included articles, page 10, line 19]
We have included our intentions for the subgroup analyses earlier in the introduction and have also outlined that a priori, lithium will not be included. "The term Nutraceutical encompasses a broad range of agents, that may have differing effects within the body on the pathophysiology of some disorders... We will present an overview of nutraceuticals broadly and then explore subgroups, based on those reported in the previous systematic review to allow comparisons with the previous literature (e.g. fatty acids). For the purposes of this review, lithium will not be included despite coming under the definition of minerals. Lithium will not be included as it has been extensively researched previously16 and will fall outside of the scope of this review." [Section: Introduction, page 5 line 8]
• On page 11, line 17, under "Sensitivity analysis," the phrasing of how the sensitivity analyses will be completed is just too vague. Please state all the comparisons you will make and the statistics you will use to compare studies. Also, state how you will handle studies that do not present separate data for gender, age, etc.
The sensitivity analysis section has been updated to include a description of how the analysis will be conducted. "Sensitivity analyses will be conducted to take into consideration the following methodological differences 1) differences in diagnostic tool (DSM vs ICD), 2) difference in BD subgroups, 3) different measures of depression (e.g. MADRS vs HADs) and 4) length of study. For each sensitivity analysis data will be analysed separately and results will be compared to the initial allinclusive analysis to ensure similar results. In addition, studies will be analysed for differences in gender, age, location, and dose of nutraceutical studied, if there are differing doses. If data for the sensitivity analysis is missing in the studies, authors will be contacted in the first instance. If more details cannot be obtained, the study will not be included in the analysis and this will be noted in the results. 
